methantheline bromide

Trade name: banthine

Small moleculeapproved

Approved

Jul 3, 1951

Methantheline is a synthetic quarternary ammonium antimuscarinic used to relieve cramps or spasms of the stomach, intestines, and bladder. It is indicated for the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children. It can be used together with antacids or other medicines, such as H2-receptor antagonists, in the treatment of peptic ulcer. Methantheline bromide (diethyl-methyl [2-(9 xanthenyl carbonyloxy) ethyl] ammonium bromide) is marketed to treat neurogenic bladder instability. In comparison with atropine, it influences the parasympathetic nervous transmission more by ganglionic rather than peripheral muscarinic receptor blockade. Methantheline inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Clinical effects after single therapeutic doses of 50-100 mg last for about 6 hours which is longer than after atropine. The drug relaxes smooth muscles of the gastrointestinal and urogenital tract. Furthermore, it inhibits bronchial, salivary and sweat glands secretion, lowers the production of gastric juice and disturbs accommodation. A recent randomised double-blind placebo-controlled study using a new commercial preparation of methantheline bromide (Vagantin, Germany) demonstrated significant sweat reduction and was evaluated as is an effective and safe treatment of axillary hyperhidrosis. — NCATS

Clinical trial activity

1 trials · 2 clinical orgs · 1 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 1999 (NCT01429090)

Timeline

1950s

  1. Jul 3, 1951

    Shire — Earliest FDA Approval

  2. Jul 3, 1951

    Shire — NDA Secondary Org

  3. Jul 3, 1951

    Shire — NDA Organization

1990s

  1. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedJul 3, 1951

Chemistry & pharmacology

Loading structure…

SMILES

CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21
Mol. weight
340.44 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • banthine
  • banthine
  • banthine
  • banthine
  • banthine
  • banthine
  • dixamon bromide
  • dixamone bromide
  • dixamone bromide
  • ethanaminium, n,n-diethyl-n-methyl-2-((9h-xanthen-9-ylcarbonyl)oxy)-
  • methanthelin
  • methantheline
  • methantheline
  • methantheline
  • methantheline
  • methantheline
  • methantheline
  • methantheline
  • methantheline
  • methantheline
  • methantheline bromide
  • methantheline bromide
  • methantheline bromide
  • methantheline bromide
  • methantheline bromide
  • methanthelinium
  • methanthelinium
  • methanthelinium
  • methanthelinium
  • methanthelinium bromide
  • methanthelinium bromide
  • methanthelinum
  • methanthelinum
  • vagantin
  • vagantin
  • vagantin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01429090Phase 1Oct 1, 1999RIEMSER Arzneimittel GmbH, University of Greifswald
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RIEMSER Arzneimittel GmbHFor profit1011999
University of GreifswaldAcademic/Hospital1111999
2 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
ShireFor profitNDA2Jul 3, 1951
ShireFor profitNDAJul 3, 1951